Cargando…

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)

Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor biology, and patient clinical characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Luigi, Vakiarou, Foteini, Zoratto, Federica, Bianchi, Loredana, Papa, Anselmo, Basso, Enrico, Verrico, Monica, Lo Russo, Giuseppe, Evangelista, Salvatore, Rinaldi, Guilia, Perrone-Congedi, Francesca, Spinelli, Gian Paolo, Stati, Valeria, Caruso, Davide, Prete, Alessandra, Tomao, Silverio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875371/ https://www.ncbi.nlm.nih.gov/pubmed/24399885 http://dx.doi.org/10.2147/CMAR.S47986

Ejemplares similares

An unusual case of spleen metastasis from carcinoma ex pleomorphic adenoma of the parotid gland
por: Rossi, Luigi, et al.
Publicado: (2014)

mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Fertility drugs, reproductive strategies and ovarian cancer risk
por: Tomao, Federica, et al.
Publicado: (2014)

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018)

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
por: Marmorino, Federica, et al.
Publicado: (2019)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
por: Chen, Hong-Hwa, et al.
Publicado: (2021)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy
por: Quirino, Michela, et al.
Publicado: (2017)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases
por: Rossi, Luigi, et al.
Publicado: (2012)

Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC)
por: Tysarowski, Andrzej, et al.
Publicado: (2018)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
por: Argiles, Guillem, et al.
Publicado: (2019)

A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report
por: Spinelli, Gian Paolo, et al.
Publicado: (2013)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
por: Bahl, Ankur, et al.
Publicado: (2020)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
por: Zhang, Yiyi, et al.
Publicado: (2021)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)
por: Miele, Evelina, et al.
Publicado: (2008)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial
por: Ferreira, Cláudia S., et al.
Publicado: (2023)

Breast cancer metastatic to the pituitary gland: a case report
por: Spinelli, Gian Paolo, et al.
Publicado: (2012)

The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site
por: Spinelli, Gian Paolo, et al.
Publicado: (2008)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
por: Feliu, J, et al.
Publicado: (2014)

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
por: Gmeiner, William H
Publicado: (2021)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

Early clear cell “sugar” lung cancer management: A case report and a brief literature review
por: Sjniari, Marsela, et al.
Publicado: (2019)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u19r9eri5i1q9t54oh646kd410